RJA
ACHV icon

Raymond James & Associates’s Achieve Life Sciences ACHV Stock Holding History

Raymond James & Associates’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$679K Sell
143,328
-7,121
-5% -$32.5K ﹤0.01% 2926
2024
Q2 		$707K Sell
150,449
-1,400
-0.9% -$6.75K ﹤0.01% 2852
2024
Q1 		$690K Sell
151,849
-2,980
-2% -$13.2K ﹤0.01% 2856
2023
Q4 		$638K Buy
154,829
+8,729
+6% +$38K ﹤0.01% 2805
2023
Q3 		$628K Buy
146,100
+8,615
+6% +$43.4K ﹤0.01% 2744
2023
Q2 		$714K Buy
137,485
+33,203
+32% +$233K ﹤0.01% 2693
2023
Q1 		$709K Buy
104,282
+15,033
+17% +$71.4K ﹤0.01% 2688
2022
Q4 		$219K Buy
89,249
+71,818
+412% +$184K ﹤0.01% 3404
2022
Q3 		$58K Buy
17,431
+4,482
+35% +$21.4K ﹤0.01% 3689
2022
Q2 		$63K Sell
12,949
-165
-1% -$1.12K ﹤0.01% 3758
2022
Q1 		$99K Buy
+13,114
New +$97.7K ﹤0.01% 3822

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's ACHV Position: Q3 2024 in Review

Raymond James & Associates reduced its Achieve Life Sciences (ACHV) stake by 4.7% in Q3 2024, selling an estimated $32.5K and leaving 143,328 shares worth $679K. The position accounts for ﹤0.01% of the portfolio, ranked #2926.

Raymond James & Associates first reported a position in ACHV in Q1 2022 and has held it in 11 quarters since. The position peaked at $714K in Q2 2023. 64 funds tracked by Wall St. Rank hold ACHV as of Q3 2024.

  • Raymond James & Associates held 143,328 shares of Achieve Life Sciences worth $679K as of Q3 2024.
  • Raymond James & Associates sold 7,121 Achieve Life Sciences shares in Q3 2024, an estimated $32.5K.
  • Achieve Life Sciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2926 holding.
  • Raymond James & Associates first reported a position in Achieve Life Sciences in Q1 2022 and has held it in 11 quarters since.
  • Raymond James & Associates's Achieve Life Sciences position peaked at $714K in Q2 2023.
  • 64 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.